Competitive Teardown — Healthtech Series A

The founder's competitive slide showed clear white space. The fund needed to test that from the buyer's chair: how do clinical and procurement leaders actually rank the company against incumbents, what makes them switch and where does the product's claimed edge stop mattering in a real purchasing decision?

• +Framed the teardown around the live buying decision, not the feature matrix
• +Sourced seven experts: clinical department leads, two health-system procurement heads and a former competitor's commercial lead
• +Asked buyers to rank the company blind against incumbents and explain the switching triggers
• +Screened for anything approaching confidential procurement data and excluded it

• +A buyer-ranked competitive map showing where the company genuinely led and where it didn't
• +The three switching triggers buyers named most often — and which the company could actually pull
• +An independent read on the incumbents' real defensive strengths versus the deck's version

• +The fund led the round, with a go-to-market thesis rebuilt around the switching triggers buyers named
• +One claimed differentiator ranked as irrelevant to buyers and was dropped from the investment case
• +The teardown reset the board's first-year commercial priorities before the money even landed

This is a representative, anonymised composite of a typical venture capital engagement. Client identity is removed and the figures illustrate the format and scale of the work — they are not a record of a single named mandate. Every expert call is scoped to general market knowledge, screened for material non-public information before findings reach a deal team, and documented for audit. See our compliance framework for full detail.